Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC

Next Previous
Search
Trial Profile

A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Diagnostic use; Therapeutic Use
  • Acronyms TARGET-NSCLC
  • Sponsors Endocyte

    • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
    • 07 Sep 2015 According to an Endocyte media release, final overall survival analysis from this trial were presented at the IASLC World Conference on Lung Cancer.
    • 07 Sep 2015 Results published in an Endocyte media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top